Amgen exits denosumab partnership

Amgen (AMGN -1.3%) ends its collaboration with Glaxo Group (GSK -0.9%) regarding the commercialization of denosumab for osteoporosis indications in certain geographies. The partnership began on July 27, 2009.

All commercial activities assigned to GSK other than those in Australia will transition back to AMGN by the end of the year.

In exchange for the early termination, AMGN will pay GSK $275M plus $15M in reimbursements for transition-related costs.

From other sites
Comments (1)
  • Charles A. Smith
    , contributor
    Comments (1276) | Send Message
 AMGN paying GSK because the D-mab market is so lucrative they want it all to themelves? Or are they paying because its a dud, and GSK wants out?
    3 Apr 2014, 01:02 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs